Clin Lab. 2020 Sep 1;66(9). doi: 10.7754/Clin.Lab.2020.191002.
BACKGROUND: Small cell lung cancer is an aggressive form of lung cancer with poor prognosis. Combined serum biomarkers may give us more information and predictive value.
METHODS: We retrospectively analyzed data and samples collected from 120 small cell lung cancer patients who had undergone surgery in Tianjin Medical University Cancer Institute and Hospital between June 2014 and November 2016. Correlations between serum biomarker levels and survival parameters were analyzed and prognostic factors were identified.
RESULTS: By univariate analysis, limited disease (p < 0.001), more than 4 cycles of first line chemotherapy (p = 0.002), thoracic irradiation (p < 0.001), PCI (p = 0.013)), higher SCCA level (p = 0.058), and normal LDH level (p = 0.027) were significantly correlated with a good PFS. By multivariate analysis, clinical stage, number of chemotherapy cycles, thoracic irradiation, PCI, and SCCA level were independent prognostic factors for PFS. Higher ProGRP or NSE level with higher LDH, higher NSE with higher D-dimer had poor prognostic index.
CONCLUSIONS: We observed that NSE, CEA, and CYFRA 21-1 were closely associated with tumor burden. The combination of NSE and ProGRP with LDH and D-dimer worked as prognostic factors for tumor progression in SCLC patients.